Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
June 2017—Fimmic launched its next-generation WebMicroscope Deep Learning Platform. Fimmic’s cloud platform brings deep learning artificial-intelligence-based image analysis to pathologists and researchers, no matter the size of a project.
June 2017—Roche received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT blood test for patients with a suspected heart attack. With this clearance, according to a company statement, Roche is the first IVD company in the U.S. to provide next-generation troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.
June 2017—Thermo Fisher Scientific released its CarrierScan Assay, a high-throughput, microarray-based assay that provides molecular genetics laboratories with a consolidated and automated single pan-ethnic solution for expanded carrier status research.
May 2017—Agena Bioscience announced a comparative study published in Scientific Reports highlighting the use of its mass-spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
May 2017—ViroStat released two sets of monoclonal antibodies to Shigella—one set specific to Shigella sonnei and another set specific to Shigella flexneri 2a. Potential applications for these include direct bacterial detection by ELISA and lateral flow rapid tests.
May 2017—Cepheid received FDA clearance to market Xpert Xpress Flu and Xpert Xpress Flu/RSV. Both tests deliver reference-quality molecular results in as little as 20 minutes. The tests are Cepheid’s first Xpress branded products, which are expected to deliver results in 30 minutes or less.
May 2017—Becton Dickinson announced that its BD Veritor System Flu A+B, a digital immunoassay for the rapid detection of influenza, meets the new FDA performance requirements in which antigen-based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from clinical specimens have been reclassified from class I devices to class II devices subject to special controls.
May 2017—Biodesix announced that its GeneStrat test, a liquid biopsy for patients with cancer, now includes ROS1 and RET. GeneStrat is a noninvasive blood test analyzing circulating tumor DNA and RNA. The test provides highly sensitive results in 72 hours for non-small cell lung cancer patients.
May 2017—Meridian has developed anti-müllerian hormone antibodies produced in chickens using a synthetic peptide representing a linear epitope on the human AMH protein. Initial purification of total IgY from eggs was followed by affinity purification against the peptide as an immunogen to yield a monospecific antibody. All antibodies can be used in ELISA.
May 2017—Sarstedt expanded its line of Multiply-µStrip PCR tubes to include a white option for qPCR. The reflective white wells maximize fluorescent signal intensity, minimize cross-talk, and enable volume reduction of expensive reagents without compromising sensitivity or stability.
